This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Clinical Information​Stroke Prevention in Atrial Fibrillation​Morbidity and Mortality​Efficacy​Aristophanes​Safety​Real-world Data​Guideline recommendations​Persistence and Adherence​Dosing​Summary​Venous Thromboembolism TreatmentEfficacySafety​Real-world Data​Guideline recommendationsDosing​Venous Thromboembolism PreventionEfficacy​Safety​Dosing​Eliquis Important Safety InformationEliquis Abbreviated Prescribing Information (2.5 mg)​Eliquis Abbreviated Prescribing Information (5 mg) Support & Services​ Support & Services​ Self-detail presentations​ Webinars​ MaterialsVideos​

Dosing Recommendations​

Stable Anticoagulation​

Eliquis® dosing recommendations and practical guidance for stroke prevention in patients with NVAF1​

Eliquis® 5 mg BID is the recommended dose for stroke prevention in NVAF1​

Dose reduction for special population1​

The recommended dose of Eliquis® is 2.5 mg taken orally BID in patients with NVAF and at least two of the following characteristics:1​

 Switching to Eliquis®1,3​

ASA: acetyl salicylic acid; BID: twice daily; INR: International Normalized Ratio; NOAC: nonvitamin K antagonist oral anticoagulant; NVAF: nonvalvular atrial fibrillation; VKA: vitamin K antagonist.​

References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J.​2018;39(16):1330-1393.​

Explore more​VTE prevention Dosing Learn more Loading
Click here for Eliquis® 2.5mg Prescribing Information

Click here for Eliquis® 5mg Prescribing Information
HF0098OA452/122022
Invalidation Date : 21/08/2024​
Quick Links
SPAF Guideline recommendations​
 Learn moreLoading
SPAF Aristophanes​
 Learn more Loading
With a half-life of 12 hours, Eliquis® twice-daily dosing gives your patients stable coverage throughout the day1​Plasma exposure and anticoagulation effects of NOACs in concentration dependent manner​3

*The mean half-life of Eliquis® has also been reported as 12 hours.1​
Twice-daily dosing was specially chosen as the optimal dosing regimen for Eliquis®5​Data From A PK/PD Study In Healthy Patients (N=36)​5*
Mean plasma concentration following multiple oral doses5
Eliquis® 10 mg QD is not approved for the prevention of stroke/systemic embolism in NVAF patients.1​

A twice-daily regimen may reduce the PK impact of missing a dose. The pharmacokinetic consequences of missing a single dose in QD regimen is equivalent to missing two or three consecutive doses of BID regimen. However, patients were only half as likely to miss two or three BID doses as one QD dose.6​PK/PD study design: The double-blind, randomised, placebo-controlled, parallel group, multiple-dose escalation study was conducted in six sequential dose panels – apixaban 2.5, 5, 10 and 25 mg BID and 10 and 25 mg QD. Subjects were randomised to apixaban or placebo for 7 days. Blood samples were taken to measure apixaban plasma concentration and for coagulation tests.​5Twice-daily vs. Once-daily dose regimen simulation​7Theoretical simulation with non-NOAC (with a half-life of 12 hours and a Tmax of 3 hours) undertaken to evaluate the PK implications of missing BID vs. QD doses7AF: atrial fibrillation; BID: twice daily; NOAC: non-vitamin K antagonist oral anticoagulant; PD: pharmacodynamic; PK: pharmacokinetic; QD: once daily; Tmax: time to maximum effect.​References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Gong IY, Kim RB. Importance of PK profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 Suppl):S24-33. 4. Xarelto® (rivaroxaban) Summary of Product Characteristics. 22 May 2016. Available at https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf Accessed August 2021. 5. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776-786. 6. Comté L, Vrijens B, Tousset E et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007;34(4):549-58. 7. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514-523.Explore more​VTE prevention Dosing​ Learn more Loading
Click here for Eliquis® 2.5mg Prescribing Information

Click here for Eliquis® 5mg Prescribing Information
HF0098OA452/122022
Invalidation Date : 21/08/2024​
Quick Links
VTE treatment Guideline recommendations
 Learn moreLoading
SPAF Guideline recommendations​
 Learn more Loading
PP-ELI-EGY-0467

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


PP-UNP-EGY-0241
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
 
PP-UNP-EGY-0241
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0241

Yes No
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241